# Clinical Trial for PB-119 in Subjects With Type 2 Diabetes Mellitus

> **NCT03059719** · PHASE1 · COMPLETED · sponsor: **PegBio Co., Ltd.** · enrollment: 36 (actual)

## Conditions studied

- Type II Diabetes Mellitus

## Interventions

- **BIOLOGICAL:** Exenatide injection(Byetta)
- **BIOLOGICAL:** PB-119 injection

## Key facts

- **NCT ID:** NCT03059719
- **Lead sponsor:** PegBio Co., Ltd.
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-04-08
- **Primary completion:** 2016-09-30
- **Final completion:** 2016-10-27
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2017-02-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03059719

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03059719, "Clinical Trial for PB-119 in Subjects With Type 2 Diabetes Mellitus". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT03059719. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*